By: Michael Izzo From: dailyrecord.com A Chester doctor has founded a nonprofit dedicated to preventing inherited cancers, instead of simply treating them after a diagnosis, which he hopes may be the first step in eliminating the disease all together. Dr. Thomas Bock’s road to creating HeritX began in November 2011, when his wife, Irina, was diagnosed with breast cancer. “I …
The Digital Divide and Breast Cancer
View PostLooking At the World Differently After Breast Cancer
View PostGlobal Non-Hematological Cancers Market Will Almost Double to $141 Billion by 2021
The global treatment market for non-hematological cancers, which includes breast, colorectal, lung and prostate cancers, among others, will almost double from $72.9 billion in 2014 to $140.8 billion in 2021, at a compound annual growth rate (CAGR) of 9.9%, according to business intelligence provider GBI Research. The company’s latest report* states that this robust growth will occur in spite of …
Short Overnight Fasting Linked to Increased Risk of Breast Cancer Recurrence
From: UC San Diego Health Sciences News Researchers suggest increasing duration of nightly fasting may improve prognosis In patients with breast cancer, a short overnight fast of less than 13 hours was associated with a statistically significant, 36 percent higher risk of breast cancer recurrence and a non-significant, 21 percent higher probability of death from the disease compared to patients …
After Breast Cancer, Nothing Is Ever the Same
View PostAcupuncture might ease hot flashes for breast cancer patients
By: Alan Mozes, HealthDay News From: upi.com Acupuncture can help alleviate the often-debilitating hot flashes that afflict many breast cancer patients, new Italian research says. Noting that hot flashes are a fact of life for many women with breast cancer, the investigators found that pairing lifestyle advice with weekly acupuncture sessions dramatically improved the women’s quality of life. “Acupuncture together …
Oasmia Pharmaceutical Announces Enrollment of First Patient in Clinical Study with Docecal, a Novel Formulation of Docetaxel
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that the first patient has been enrolled in the Phase I clinical study of the Company’s next-generation cancer treatment candidate Docecal, to be performed internationally. Docecal was approved for clinical trials in December, 2015. Docecal is a nanoparticle and water-soluble …
Early Warning Signs Don’t Always Exist With Cancer
Barbara JacobyBarbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide. LetLifeHappen.com